Forskning
Udskriv Udskriv
Switch language
Rigshospitalet - en del af Københavns Universitetshospital
Udgivet

Increase of Ki-67 index and influence on mortality in patients with neuroendocrine neoplasms

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

DOI

  1. Photoperiodic co-regulation of kisseptin, neurokinin B and dynorphin in the hypothalamus of a seasonal rodent

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. Distribution and seasonal variation in hypothalamic RF-amide peptides in a semi-desert rodent, the jerboa

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  3. Mapping of kisspeptin fibres in the brain of the pro-oestrus rat

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  4. Characterization of the uptake of DADLE to isolated nerve terminals - morphine stimulates uptake

    Publikation: Bidrag til tidsskriftKonferenceartikelForskningpeer review

  1. Constitutional POLE variants causing a phenotype reminiscent of constitutional mismatch repair deficiency

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. Brain tumours in children and adolescents may affect the circadian rhythm and quality of life

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

Vis graf over relationer

An increase in the Ki-67 index in neuroendocrine neoplasms over time in relation to prognosis has scarcely been investigated. We aimed to assess whether the Ki-67 index changed over time and also whether a change influenced prognosis. Second, we investigated the difference in the Ki-67 index between primary tumour and metastases. From 1 January 1995 to 31 December 2019, 108 consecutive patients with gastroenteropancreatic tumours were included. Patients were followed with regard to an increase in the Ki-67 index and all-cause mortality. Ki-67 determination of the primary tumour at diagnosis and at the time of radiological progression, including developed metastases, was performed. A significant increase in the Ki-67 index was defined as a doubling of the value at disease progression compared to the value at diagnosis. In addition, in 14 patients, the Ki-67 index of the primary tumour and present metastases at the time of diagnosis was investigated. At diagnosis, there were no differences in the Ki-67 index between primary tumours and metastases (P = .41). Sixty-five patients had a doubling of the Ki-67 index. The median Ki-67 index at the time of progression 17% (1%-90%) vs 5% (1%-60%) at the time of diagnosis (P = .006). A doubling of the Ki-67 index was independently associated with all-cause mortality (hazard ratio = 2.7 [1.3-6.3], P = 0.02), after adjustment for relevant co-variables including the Ki-67 index at baseline. Doubling of the Ki-67 index at the time of disease progression was associated with a significantly higher risk of all-cause mortality. We recommend that a Ki-67 index is obtained whenever disease progression is recorded by demonstrated progression because it may have impact on the choice of treatment.

OriginalsprogEngelsk
Artikelnummere13018
TidsskriftJournal of Neuroendocrinology
Vol/bind33
Udgave nummer9
Sider (fra-til)e13018
ISSN0953-8194
DOI
StatusUdgivet - 26 jul. 2021

Bibliografisk note

© 2021 British Society for Neuroendocrinology.

ID: 68601249